Showing posts with label Sprint Fidelis. Show all posts
Showing posts with label Sprint Fidelis. Show all posts
Wednesday, March 31, 2010
Eighth Circuit Sets New Date for Oral Argument on Appeal of Federal Case Dismissal
The Eighth Circuit Court of Appeals has notified the parties of a new date for oral argument in plaintiffs’ appeal of the dismissal of complaints against Medtronic for its faulty heart devices. The appeal will now be heard on April 12, 2010, in St. Louis, Missouri. Oral argument had originally been set for January 2010. The state court appeal date has not yet been scheduled. The parties are still briefing their sides of the case.
Monday, June 30, 2008
Critics blast feds' legal shields for manufacturers
On June 29, 2008, the Chicago Tribune published an article recapping Bridget Robb's horrific tale of being shocked 31 times in 13 minutes due to a faulty, Medtronic Sprint Fidelis Lead. The article is one of many discussing how injured people, like Ms. Robb, are many times are precluded from recovering for their injuries due to a legal doctrine called "preemption." In effect, injured individuals are precluded from recovering against a company for defects in a product's design and labeling.
Proponents of preemption argue that manufacturers are not insurers and the FDA always has the option of holding a product from the market. During the June 11, 2008 Senate Judiciary Committee hearing at which Ms. Robb testified, Senator Specter called the FDA a joke and said that it is ludicrous to have preemption by an agency that is dysfunctional.
Before the hearing abruptly came to a halt because of a 2-hour rule invoked by a certain Republican Senator, Senator Whitehouse discussed "Regulatory Capture" -- which is when an agency that purports to be a public agency is taken over by the groups it was meant to regulate. Senator Whitehouse believes that the FDA falls within this definition.
Proponents of preemption argue that manufacturers are not insurers and the FDA always has the option of holding a product from the market. During the June 11, 2008 Senate Judiciary Committee hearing at which Ms. Robb testified, Senator Specter called the FDA a joke and said that it is ludicrous to have preemption by an agency that is dysfunctional.
Before the hearing abruptly came to a halt because of a 2-hour rule invoked by a certain Republican Senator, Senator Whitehouse discussed "Regulatory Capture" -- which is when an agency that purports to be a public agency is taken over by the groups it was meant to regulate. Senator Whitehouse believes that the FDA falls within this definition.
Monday, June 16, 2008
BRIDGET ROBB TESTIFIES BEFORE THE SENATE JUDICIARY COMMITTEE ABOUT INJURIES FROM DEFECTIVE MEDTRONIC SPRINT FIDELIS LEAD
On June 11, 2008, I had the pleasure of accompanying Bridget Robb, one of my clients, to Washington, D.C. to testify before the Senate Judiciary Committee, at a hearing entitled “Short-change for Consumers and Short-Shrift for Congress? The Supreme Court’s Treatment of Laws that Protect Americans’ Health, Safety, Jobs and Retirement.” Senator Patrick Leahy (D, Vt.) presided over the hearing. Witness testimony and the live hearing can be viewed at http://judiciary.senate.gov/hearing.cfm?id=3404
Ms. Robb courageously spoke about her harrowing experience with a Medtronic Sprint Fidelis lead in late 2007. Ms. Robb was shocked 31 times due to the defective cardiac lead, which had been recalled two months before her tragic incident. She never received notice of the recall. She described each shock as “if a cannon was being repeatedly shot at [her] chest at close range.” The event was made all the more terrible because our client’s telephone call to 911 was captured on tape, and the pain and agony of the numerous shocks is evident throughout the 7-minute call, which took place in the presence of her young child. Her experience was featured in a Good Morning America segment that ran on Wednesday morning before the hearing, which can also be viewed on the web at http://abcnews.go.com/GMA/OnCall/story?id=5044693&page=1
The hearing focused on how several recent decisions by the U.S. Supreme Court affected consumers’ health and safety, including preemption and ERISA.
Senator Leahy stated that he “called this hearing today to shine a light on how the Supreme Court’s decisions affect Americans’ everyday lives. Often, the Court’s rulings come into focus when they involve divisive cultural issues. Lately, however, many Court observers have noticed that business interests have been the big winners, over workers and consumers. In this worsening economy, mothers and fathers are struggling with health care coverage, the uncertainty of retirement, credit card payments and mortgages. Congress has passed laws to protect Americans in these areas, but in many cases, the Supreme Court has ignored the intent of Congress in passing these measures, oftentimes turning these laws on their heads, and making them protections for big business rather than for ordinary citizens.” During the hearing, Sen. Arlen Specter (R., Pa.) also spoke out forcefully on the failings of the FDA, calling the FDA "a joke."
Also testifying was Maureen Kurtek, a Harrisburg, Pennsylvania, resident, who offered personal testimony about how a recent ruling by the Supreme Court relating to ERISA preemption limited her right as a consumer to seek recovery for harmful practices by an HMO. Other witnesses include Andy Anderson, a lawyer with the law firm of Morgan, Lewis & Bockius LLP; Thomas O. McGarity, a law professor at the University of Texas School of Law; Richard M. Cooper, a partner with the law firm of Williams & Connolly LLP; and Robert Lawless, a law professor at the University of Illinois College of Law.
This hearing helped shed light on the profound effect that the failures of the Food & Drug Administration have on consumers, like Ms. Robb.
I am happy to answer any questions regarding the hearing or the recalled Medtronic Sprint Fidelis lead. Please contact me at (215) 790-7379 with any questions or to discuss your potential case. It is important that the horrible tragedy Ms. Robb experienced does not happen to others.
Labels:
Bridget Robb,
cardiac lead,
FDA,
Medtronic,
Preemption,
Sprint Fidelis
Monday, December 3, 2007
Recall of Medtronic Sprint Fidelis Lead Wires Exceed 250,000 Worldwide

On October 15, 2007, Medtronic issued a recall of its Sprint Fidelis defibrillator leads as a result of at least five patient deaths in which a lead fracture may have been a contributing cause. Sprint Fidelis Leads are certain models of cardiac electrodes (thin wires) that connect an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) directly to the heart. The recalled leads have been implanted in over 200,000 patients since 2004. Most patients with Medtronic defibrillators since 2004, and most patients who received Medtronic defibrillators since then have these leads. A small number of Sprint Fidelis leads are also used with defibrillators made by manufacturers other than Medtronic.
Medtronic estimates a 2.3 percent failure rate in patients with the Sprint Fidelis lead, or 4000 to 5000 people, will experience a lead fracture within 30 months of the device implantation. Replacement of the lead is a serious and delicate procedure which is far more dangerous than replacing the device itself because the lead wires are thread into the interior chamber of the heart.
Generally, patients with heart devices are issued device identification cards that will contain information about their heart device and leads. Patients can check this wallet card for the model number to see if their leads are under recall. The recalled leads are Sprint Fidelis Lead Model Nos. 6930, 6931, 6948 and 6949. These numbers may be shown at the beginning of a longer set of numbers on a patient's identification card.
Complaints against the company allege that a design defect is responsible for the lead fractures. The complaints also allege that Medtronic failed to act timely in recalling the lead as it has known of a large number of failures of the device since at least the end of 2006.
If you would like additional information regarding the aforementioned recall, or would like to speak to an attorney regarding bringing a potential case against Medtronic associated with the implantation of a Sprint Fidelis lead, please contact me directly.
Claudine Q. Homolash has successfully represented hundreds of patients across America who received faulty or recalled medical devices, including implantable cardiac defibrillators and pacemakers.
Labels:
defibrillator,
heart device,
Medtronic,
Sprint Fidelis
Subscribe to:
Posts (Atom)